Nutriband Inc. Files Provisional Patent to Strengthen Protection of AVERSA™ Abuse-Deterrent Technology

Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has filed a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA™ abuse-deterrent transdermal technology. The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering. If converted to a non-provisional patent and granted, the new patent could extend AVERSA’s protection by up to 20 years from the filing date.

AVERSA™ technology, already patented in 46 countries, incorporates aversive agents into transdermal patches to prevent misuse of drugs with abuse potential while maintaining accessibility for patients who require them. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating this technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The expanded patent protection comes at a critical time as the pharmaceutical industry continues to address the ongoing opioid crisis and the need for safer pain management solutions. By strengthening the intellectual property portfolio around AVERSA™ technology, Nutriband positions itself to better compete in the growing market for abuse-deterrent formulations. The technology represents an important advancement in balancing patient access to necessary medications while implementing safeguards against potential misuse.

For more information about the company, visit https://www.nutriband.com. The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB. This patent filing represents a strategic move to protect the company's core technology and maintain its competitive advantage in the transdermal pharmaceutical market. The enhanced formulations and application methods covered by the provisional patent could further differentiate Nutriband's products in a market increasingly focused on safety and abuse prevention.